WallStSmart

CryoCell International Inc (CCEL)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Universal Health Services Inc generates 58094% more annual revenue ($18.11B vs $31.13M). UHS leads profitability with a 8.4% profit margin vs -7.9%. UHS appears more attractively valued with a PEG of 1.19. UHS earns a higher WallStSmart Score of 72/100 (B).

CCEL

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

UHS

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.76
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.9%)

Margin of Safety

+33.9%

Fair Value

$5.05

Current Price

$3.99

$1.06 discount

UndervaluedFair: $5.05Overvalued
UHSSignificantly Overvalued (-24.1%)

Margin of Safety

-24.1%

Fair Value

$186.39

Current Price

$181.39

$5.00 premium

UndervaluedFair: $186.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
72.1%10/10

Earnings expanding 72.1% YoY

Debt/EquityHealth
-0.5010/10

Conservative balance sheet, low leverage

UHS3 strengths · Avg: 9.7/10
P/E RatioValuation
7.1x10/10

Attractively priced relative to earnings

Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Return on EquityProfitability
20.2%9/10

Every $100 of equity generates 20 in profit

Areas to Watch

CCEL4 concerns · Avg: 2.0/10
Market CapQuality
$35.48M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

Profit MarginProfitability
-7.9%1/10

Currently unprofitable

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Price/Book, Return on Equity. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bear Case : CCEL

The primary concerns for CCEL are Market Cap, Revenue Growth, Altman Z-Score.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while UHS is a value play — different risk/reward profiles.

UHS carries more volatility with a beta of 1.06 — expect wider price swings.

UHS is growing revenue faster at 8.3% — sustainability is the question.

UHS generates stronger free cash flow (216M), providing more financial flexibility.

Bottom Line

UHS scores higher overall (72/100 vs 50/100). CCEL offers better value entry with a 33.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?